🟢 Context Therapeutics is trading 7.98% up today; immediate trigger remains unclear

Context Therapeutics is trading 7.98% up at $0.38, following a September 14 close of $0.35; the immediate trigger remains unclear.

• No new company-specific announcement or clearly reported catalyst was identified for September 15.
• The latest release remains the September 9 first-patient dosing announcement for the CT-202 Phase 1 trial, several sessions old.
• Broader U.S. markets are modestly lower.